Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.38 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | STAT6 | P42226 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915914 | 0.73 | GRIN2D (0.42) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL31254406 | 0.73 | SIGMAR1 (0.42) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5598597 | 0.69 | SIGMAR1 (0.38) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13428595 | 0.69 | SIGMAR1 (0.38) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL15827308 | 0.69 | GRIN2D (0.38) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2479820 | 0.69 | SIGMAR1 (0.45) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL12439809 | 0.69 | SIGMAR1 (0.38) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4972287 | 0.69 | SIGMAR1 (0.38) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL985712 | 0.67 | ABL1 (0.39) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL985710 | 0.67 | ABL1 (0.39) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| EP-0023569-B1 | DERIVATIVES OF CARBOXYLIC ACIDS, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1983-06-22 | — | — | EP | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20040110229-A1 | Muscarinic receptor antagonists | PNC BANK, NATIONAL ASSOCIATION | 2004-06-10 | — | — | US | disclosed |
| US-6693202-B1 | MULTIBINDING LIGANDS CONTAINING SUCH AS AMINE, AMIDE, ESTER, HYDROXYL, CARBAMATE, UREA AND/OR IMINO FUNCTIONALITY | THERAVANCE, INC. | 2004-02-17 | — | — | US | disclosed |
| EP-1019358-B1 | 3,3-DIARYLPROPYLAMINES , THEIR USE AND PREPARATION | PHARMACIA AB (SE) | 2003-05-07 | — | — | EP | disclosed |
| US-6313132-B1 | FOR THERAPY OF URINARY INCONTINENCE, ACETYLCHOLINE-MEDIATED DISORDER | PHARMACIA AB (SE) | 2001-11-06 | — | — | US | disclosed |
| EP-1086066-A4 | MUSCARINIC RECEPTOR ANTAGONISTS | ADVANCED MEDICINE INC (US) | 2001-08-08 | — | — | EP | disclosed |
| EP-1086066-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1019358-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia & Upjohn AB (SE) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999064043-A9 | MUSCARINIC RECEPTOR ANTAGONISTS | ADVANCED MEDICINE INC (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999064043-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1998043942-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | PHARMACIA & UPJOHN AB (SE) | 1998-10-08 | — | — | WO | disclosed |
| EP-0023569-B1 | DERIVATIVES OF CARBOXYLIC ACIDS, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1983-06-22 | — | — | EP | disclosed |
| EP-0023569-A1 | Derivatives of carboxylic acids, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1981-02-11 | — | — | EP | disclosed |
| US-3941885-A | N-ADAMANTANYL AMINO ALKANOIC ACID | SCHERING CORPORATION (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110229-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | SIGMAR1 407/4885GRIN2D 611/4885GRIN3B 231/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | SIGMAR1 407/4885GRIN2D 611/4885GRIN3B 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.